GaMF1.39’s antibiotic efficacy and its enhanced antitubercular activity in combination with Clofazimine, Telacebec, ND-011992 or TBAJ-876

• Main Authors: Ragunathan, Priya, Ng, Pearly Shuyi, Singh, Samsher, Poh, Wee Han, Litty, Dennis, Kalia, Nitin Pal, Larsson, Simon, Harikishore, Amaravadhi, Rice, Scott A., Ingham, Philip William, Müller, Volker, Moraski, Garrett, Miller, Marvin J., Dick, Thomas, Pethe, Kevin, Grüber, Gerhard
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2023
• Subjects: Science::Biological sciences::Biochemistry; Bioenergetics; Mycobacterium Tuberculosis; Tuberculosis; F-ATP Synthase; Oxidative Phosphorylation; Aanti-TB Compound
• Online Access: https://hdl.handle.net/10356/172412
• Institution: Nanyang Technological University

The Mycobacterium tuberculosis (Mtb) F-ATP synthase generates most of the biological energy currency ATP. Previously, we identified the mycobacterium-specific loop of the F-ATP synthase subunit γ as a new anti-tuberculosis target, discovered the novel diaminopyrimidine GaMF1,whose potency was improved by structure-activity relationship studies leading to the analogue GaMF1.39. Here, we report that GaMF1.39 depletes cellular ATP formation by targeting the mycobacterial F-ATP synthase, without affecting proton-coupling or oxygen consumption. The antimycobacterial compound is bactericidal and potent against Mtb in macrophages, without inducing phenotypic changes in biofilm formation, planktonic bacteria or being toxic to zebrafish larvae. Combining GaMF1.39 with the NADH Dehydrogenase inhibitor clofazimine, the cyt- bcc:aa3 inhibitor Telacebec, or the F-ATP synthase inhibitor TBAJ-876 showed enhanced whole ATP synthesis inhibition and anti-tuberculosis activity. These results suggest that GaMF1.39 may add value to a compound combination targeting oxidative phosphorylation for tuberculosis treatment.